{"name":"Innovaderm Research Inc.","slug":"innovaderm-research-inc","ticker":"","exchange":"","domain":"","description":"Innovaderm Research Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative dermatological products. The company has a diverse pipeline with six drugs in various stages of development, including marketed and phase 3 products.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Adalimumab Every Week","genericName":"Adalimumab Every Week","slug":"adalimumab-every-week","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Adalimumab every other week","genericName":"Adalimumab every other week","slug":"adalimumab-every-other-week","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Eucerin","genericName":"Eucerin","slug":"eucerin","indication":"Other","status":"marketed"},{"name":"Placebo / Xeomin","genericName":"Placebo / Xeomin","slug":"placebo-xeomin","indication":"Cervical dystonia","status":"phase_3"}]}],"pipeline":[{"name":"Adalimumab Every Week","genericName":"Adalimumab Every Week","slug":"adalimumab-every-week","phase":"phase_3","mechanism":"Adalimumab is a TNF-alpha inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.","indications":["Rheumatoid arthritis","Psoriasis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis"],"catalyst":""},{"name":"Eucerin","genericName":"Eucerin","slug":"eucerin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adalimumab every other week","genericName":"Adalimumab every other week","slug":"adalimumab-every-other-week","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Placebo / Xeomin","genericName":"Placebo / Xeomin","slug":"placebo-xeomin","phase":"phase_3","mechanism":"Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Glabellar lines (aesthetic indication)","Crow's feet (aesthetic indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNcTJnVHl4bUFFbF93Y2V4RlpsZDB1ektuNTI4VzB5aXlfUjU4NnF2Z3QwY3VISmw3dkhLT1dfTU5FdlkyWVc1bEU5UW80MzY4R1VtSTRKZXc4RnVrRUJqdHFma0EyTkpLbkRqY1ZiTDlFUHN6QmxDaXV5OG5mTGdhMmgwNTVEOVBQS0dDQ3NMbExHQmhvNWZlcGhadHBnUjAyR3pTS1VnbUIwbUhjYnRrRG5qMmtVMUFCRkJOZExzUW03VjNzRlY2NHhXa1R3dF9mVjJsdkg1REpCLVZVaTEwNlgzdTJRWkJyVzBjMGFkVVJwdE9ka1QtdllYNmFhT1dZc2Y3ckFXb3pHLUFtV1NZNFJiTExkVHBaMjQ3SUdNQ0pHelVleTN5NTMwQjRLU1UzX0ZRdGhqSjY5VEx0d1dncXJZYUdfQm5BbzdhZ1hyQQ?oc=5","date":"2026-03-23","type":"regulatory","source":"Barchart.com","summary":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - ","headline":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1FUHIzWUVnRUNDaXR2Y2hSR0xMbWxQYm55TGZwUkdGREJWTFJpTkFudW1HWHNPRHI5SUZWdXFJeVJVWjJLVmJfcTZKVHRrQ19QV1I4eUgzTzNqTC1Qa3QxQVdaTXhIRGpCeVE?oc=5","date":"2025-08-28","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQbDBMN29TWTBsOFBnUVFGZmpqQ2dQX2MtZEpUdW5ZRWVoODRQXzJXMktOWWN4d0ZPLUdZUHNxeXNURUYwWnFodzZ2Vm04aVQ0UnRhQk5aaDIzVklfM2dmcmdzOEhibVRGM25LYndxZWpCZDlWdXBUUVN0b1l0a3ZQV0tTeFNFQ1k?oc=5","date":"2025-03-24","type":"trial","source":"Harvard Medical School","summary":"Study Identifies Gut Sensor That Propels Intestines To Move - Harvard Medical School","headline":"Study Identifies Gut Sensor That Propels Intestines To Move","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOMDZ0WUFTMWxkT01PVWUxZDVpblVUU3U1SXEteWNIc1VmWHJHTnB4dnNkamxHdUdMRnZEMFpySHBKZXpJa1pjbUUwdnM1cWJrTzJORjJ5OVA5WE5VcEt4enc4a3YzOUZsc3ZxdmtJUWoyN3BJY19abWUxY081UDk3eVgwOUxVNC1YM1NWRlF1OGFTS0ZMZmk3LWFkWjZXWkYxT1RkcUpXcGs3cTd4bVJBcnpR?oc=5","date":"2025-03-07","type":"pipeline","source":"Business Wire","summary":"Innovaderm Research Rebrands as Indero, a Dual-Focus CRO - Business Wire","headline":"Innovaderm Research Rebrands as Indero, a Dual-Focus CRO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcjdZOERrR3QySXRNTi1xMTJDM1ZncGJPZ0hEaUZiLWdNUWhJOWpLOU9pQU5ONzV3TWctekdlQTBCYU1uRXFqTkxnMFgxYVN2SVpPQjJySE04YmMyOC1HS1RpOFRieGJYanRrYnlWUE1VLVRwb3VnS0RUWENZeGl1UG1SbFJUWmhPUG1aMWJiYU5lbjNQMUQ2YXlKcVBVQU5pMzNxYmJNN21DTnZ4bWtESUw1aUtUZVZZdHJLeS1jMS1fUQ?oc=5","date":"2025-01-29","type":"pipeline","source":"Healio","summary":"‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders - Healio","headline":"‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5tRkVIdmQ2ZWNmRlVSZ296bWdIa012OEpyQW4wSENYVXg3cnhFN0U5V2xkSFpneldUSERHR2ozVU5iY1NCeVFHX25feVZHTUNiRElyVlgtOHNIMUpOSVdZX1NDTzRoNkVBWkdXXw?oc=5","date":"2023-11-20","type":"trial","source":"Wiley Online Library","summary":"Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study - Wiley Online Library","headline":"Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTmZoLWt0cnVJSGJSM3VSSjZZaHpKZ2dGRGsxck45eThjdXNia3lRZDAxOU4tWG1FUmhGcEgxa3hBLXAzV0NHNzRjclFUd0NmT1FZU1V4S0FXNzFxdWh4TDlOdDRfSEpXaDVKbG8zS291QTlwZzVaMFNTQ0xsUXFOVE5qaGZPWDU4UEFodDF6Y1owWTFyZk11azdYY0RMNVhPbXkzUW5WRzNTTGdiR2MxaUdJV2R3dWhSZENzd2lORFN4SEE?oc=5","date":"2023-03-19","type":"pipeline","source":"Healio","summary":"Eli Lilly’s novel eltrekibart shows early promise in hidradenitis suppurativa - Healio","headline":"Eli Lilly’s novel eltrekibart shows early promise in hidradenitis suppurativa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1wVVdHR0k5SUpxbEtnS1o4NUVsQzloMVR3dk40Vl9janllRlpRTEdwRVMxQUpDMXljN25fQV9KMUc0UDZwV29yR1JDU25hYTdhWTRfeEhXd21JaWZMZXVOQlFlWkVaRkc5N3c?oc=5","date":"2022-11-14","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}